Symbols

RYTM

Rhythm·NASDAQ

--(--)

RYTM fundamentals

RYTM Q4 2025 Earnings

Rhythm (RYTM) released its earnings on Feb 26, 2026: revenue was 57.25M (YoY +36.87%), beat estimates; EPS was -0.73 (YoY -1.39%), beat estimates.

Revenue / YoY

57.25M

+36.87%

EPS / YoY

-0.73

-1.39%

Report date

Feb 26, 2026

RYTM Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 revenue up 12% QoQ, 50% YoY, driven by global IMCIVREE expansion.
Pipeline Momentum: Bivamelagon Phase 3 on track for mid-2026 data; Japan/Europe reimbursement programs pending approval.
Financial Expansion: R&D/Sales expenses +35% YoY due to clinical trial growth and commercial infrastructure build-up.
Regulatory Focus: Acquired HO PDUFA March 2026; Japan/Europe reimbursement programs pending.

Earnings

EPS

Revenue

Revenue & Expenses

RYTM has released its 2025 Q4 earnings report, with revenue of 57.25M, reflecting a YoY change of 36.87%, and net profit of -47.51M, showing a YoY change of -9.73%. The Sankey diagram below clearly presents RYTM's revenue sources and cost distribution.

Key Indicators

Rhythm (RYTM) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Rhythm (RYTM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Rhythm (RYTM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Rhythm (RYTM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown